 | | Vol. 8.36 – 14 October, 2022 |
| |
|
|
| The authors showed that the subset of intraepithelial lymphocytes that expressed γ and δ T cell receptor subunits promoted the viability of Paneth cells deficient in the Crohn’s disease susceptibility gene ATG16L1.
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers identified novel circRNAs that can control liver metastatic colorectal cancer and discovered two anti-metastatic circRNAs generated from PPFIA1.
[Molecular Cancer] |
|
|
|
| H2DCFDA staining, and Mito-Tracker Red staining were carried out to evaluate mitochondrial membrane potential, intracellular reactive oxygen species level, and mitochondrial morphology.
[Cancer Cell International] |
|
|
|
| Scientists utilized 3D printing and inverse molding techniques to form 3D spongy scaffold systems that resemble the intestinal crypt-villus microarchitecture.
[ACS Biomaterials Science & Engineering] |
|
|
|
| The authors tested the potency of morin to inhibit cancer stem cells. They found that morin had significantly reduced colon cancer cell proliferation, colony formation, migration, and colonospheroid formation in a dose-dependent manner.
[Medical Oncology] |
|
|
|
| Researchers studied the FEZF1-AS1/miR-92b-3p/ZIC5 axis. They detected the expression of FEZF1-AS1, miR-92b-3p, and ZIC5 via quantitative reverse transcription-PCR, and performed functional assays.
[Molecular and Cellular Biochemistry] |
|
|
|
|
| The authors review the regulatory roles of signaling pathways in gastric cancer potential biomarkers, and therapeutic targets with an emphasis on recent discoveries.
[Signal Transduction and Targeted Therapy] |
|
|
|
| Investigators present an overview of the current evidence supporting the role of neurotransmitters in colorectal cancer biology and treatment.
[Oncogene] |
|
|
|
|
| VectivBio Holding AG announced positive interim data from the company’s ongoing Phase II STARS Nutrition study evaluating the safety, pharmacokinetics, and efficacy of apraglutide, an investigational new drug, a next-generation, long-acting synthetic GLP-2 agonist, in adult patients with SBS-IF and CIC.
[VectivBio Holding AG] |
|
|
|
| Iterative Scopes announced that it has partnered with One GI®, a gastroenterology management services organization to bring its AI Recruitment technology to One GI’s clinical research..
[Iterative Scopes (Business Wire)] |
|
|
|
|
| November 7 – 9, 2022
Singapore, Singapore |
|
|
|
|
|
| | Colgate University – Hamilton, New York, United States |
|
|
|
| | Brigham and Women’s Hospital – Boston, Massachusetts, United States |
|
|
|
| | University of Colorado Denver – Aurora, Colorado, United States |
|
|
|
| | CancerCare Manitoba Research Institute – Winnipeg, Manitoba, Canada |
|
|
|
| | The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
